
    
      -  Following satisfaction of entry criteria, all subjects at the Baseline/Screening visit
           will be randomized 1:1 to receive either Taclonex® (calcipotriene 0.005% and
           betamethasone dipropionate 0.064%) Ointment or Taclonex Scalp® (calcipotriene 0.005% and
           betamethasone dipropionate 0.064%) Topical Suspension to use once daily for three days
           to affected areas of the body, excluding face and intertriginous areas. Subjects will be
           aware of which product they are using. Investigators will remain blinded.

        -  Subjects will be randomized to use either the ointment or the scalp suspension for the
           first three day treatment period, then cross over to use the other product for second
           three day treatment period.

        -  Each medication will be used within its FDA-approved label for the treatment of plaque
           psoriasis in subjects aged 18 and older. Subjects may not treat areas of the face,
           axilla or groin in this study.

        -  At the Day 3 and Day 6 visits the subjects will complete a questionnaire about their
           psoriasis treatment preferences.

        -  Pregnancy tests will be done on females of childbearing potential at Baseline/Screening.

        -  Adverse events will be monitored at each visit.
    
  